selectabio.com - RNAC Enterprise Value-to-Sales Ratio

Public company logo of Selecta Biosciences (RNAC)

A unique approach to RNA cell modification protects Cartesian Therapeutics (RNAC) from price competition. This EV/Sales chart demonstrates the resilience of the business model, where the indicator reaches 127000.00. This confirms the strategy of creating safe CAR-T products with transient expression. Future financial growth will be driven by the commercialization of mRNA therapies, particularly for the treatment of severe myasthenia gravis.

selectabio.com (RNAC): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/19/2026

Financial and market metric breakdowns for Cartesian Therapeutics Inc (RNAC)

Fundamental valuation:Cartesian Therapeutics (RNAC)
Core merchandise of Selecta Biosciences

Cartesian Therapeutics (RNAC) reduces regulatory risks by diversifying its pipeline between oncology and neurology, which directly impacts its market value. The EV/Sales metric measures the total enterprise value, including debt, relative to annual revenue to assess capitalization efficiency. The value of 127000.00 helps determine the degree of asset overheating and the probability of a correction. Holding key levels confirms the stability of the company's capital. The EV/Sales multiple dynamics on the GURU.Markets platform serve as a navigator for the conservative investor.